Misiu, the HC analyst does follow the company close. I believe it is Yi Chen and he has asked some good questions during the investor calls. During a recent rating (and likely this one too) they provide the details and assumptions of their calculation. I do believe he is wrong, but remember this is only his $1.00 price projection is only 12 months, and probably very conservative to cover his tail. My guess is the BLA delay and revenue not until the end of 2Q 2020 is the reason for the decrease from $1.50 to $1.00. 12 months from now we may only beginning to ramp up leronlimab sales and may not even have 3 months sales data yet.

I believe and hope we will be much higher before the end of 2019...but no professional analyst is going to put his neck on the line to recommend $2-3 in the next three months.